Actively Recruiting
Efficacy and Safety of EsoDuo®
Led by Chong Kun Dang Pharmaceutical · Updated on 2024-05-28
180
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid
CONDITIONS
Official Title
Efficacy and Safety of EsoDuo®
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or Female aged 69 19 years
- Patients diagnosed with non-erosive reflux disease or mild erosive reflux disease
- Episode of heartburn the GERD symptom(either heartburn or gastric acid reflux)
You will not qualify if you...
- Surgery history on stomach or esophagus
- Barrett's esophagus (over 3cm), esophageal varices, esophageal stricture, esophageal achalasia, eosinophilic esophagitis, and primary motility disorders
- Patients diagnosed with Grade C or Grade D according to the LA Classification system during upper gastrointestinal endoscopy
- Patients with a history of malignancy within the past 5 years prior to the screening visit (Visit 1)
- Patients who have taken prohibited concomitant medications within 14 days prior to the screening visit or require continuous administration of prohibited medications during the trial period.
- Clinically significant Abnormal Lab test
- Pregnant woman, Breastfeeding woman.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Asan Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
H
Hwoon-Yong Jung, M.D, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here